ZORTRESS
LOE ApproachingNDAORALTABLET
Approved
Apr 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZORTRESS (everolimus) is an oral small-molecule protein kinase inhibitor approved in 2010 for transplant rejection prevention and certain cancers. It works by inhibiting mTOR signaling, a key pathway in cell proliferation and immune response. The drug is indicated across multiple therapeutic areas including oncology and immunosuppression.
$0.002BPart D
LOE ApproachingDeclining
As LOE approaches, ZORTRESS teams are transitioning to lifecycle extension and generic preparation strategies, with reduced commercial headcount expectations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
Started Mar 2019
9 enrolled
End Stage Renal DiseaseKidney Transplant
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
Started Nov 2016
1 enrolled
Kidney Transplant RejectionGastrointestinal Disorder, Functional
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
Started Mar 2016
28 enrolled
Liver Transplantation
Career Relevance
Working on ZORTRESS offers limited growth opportunities due to LOE-approaching status and crowded competitive landscape with stronger alternatives. Career mobility may be constrained as Novartis scales back investment in this aging asset.
Worked on ZORTRESS at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.